- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06111092
Prueba de la metodología del pensamiento de diseño para involucrar a familias hispanas y latinas de niños autistas en la investigación.
The goal of this study is to compare two methods of engagement in research that include autistic individuals, Hispanic and Latino parents of autistic children, occupational therapy clinicians, teachers, and to use the information collected in the sessions to culturally adapt the occupational therapy Ayres Sensory Integration intervention to improve participation and health outcomes.
The main questions it aims to answer are:
Does the Design Thinking process result in higher stakeholder engagement and satisfaction in the research process in comparison to Focus Groups? Secondary question: Do cultural adaptations using DT data yield higher acceptability and implementation feasibility scores than FG methods?
Participants will:
- Be randomized into two groups of engagement (focus groups and design thinking)
- Be blinded (clinicians, selected caregivers, autistic persons, and cultural experts) and will rate the culturally adapted manualized protocol and evaluate the acceptability, feasibility, and cultural appropriateness of each protocol based on DT data, higher than the protocol based on FG data.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Racial and ethnic minorities with autistic children experience delays in access to therapy services that can result in poorer outcomes, decreased quality of life, and increased parental and financial stress. Many autism interventions were developed and tested with only White participants, assuming they could be transferable to minority populations. However, research has found that this is not the case and that interventions that are not adapted to an individual's culture and ethnicity do not work as well and are not used as frequently. In this project, we compare two methods of stakeholder engagement, Design Thinking (DT) and Focus Groups (FG), to determine which is better at getting input on the facilitators and barriers to access therapy for autistic children. We focus on Hispanics and Latinos as this is the largest minority group in the US, with one of the fastest-growing groups of autistic children. Our long-term objective is to improve the functional skills and health of Hispanic/Latino autistic children and their families by improving access to an occupational therapy intervention designed to improve daily living skills, socialization, and quality of life. Occupational therapy using Ayres Sensory Integration (OT/ASI) is the only evidence-based intervention that addresses the sensory symptoms in autism. We will use input from these engagement sessions to adapt two versions of the OT/ASI manual: one using DT data and the other using FG data. Outcomes are evaluated following each step. Following the completion of this project, the planned outputs of the study are data on the most effective minority stakeholder engagement method and a culturally adapted OT/ASI manual for Hispanic and Latino autistic children for clinicians and researchers. This information can support future researchers who are engaging Hispanic/Latino individuals or other minority groups in research.
Methods: A randomized mixed methods design is used to evaluate stakeholder engagement methods. Phase one will compare two stakeholder engagement methods (Design Thinking -DT, and Focus Group - FG) and evaluate stakeholder engagement based on the PCORI areas of stakeholder engagement which are operationalized in the Stakeholder-Centric Engagement Evaluation and qualitative data. Phase two utilizes data from phase one to culturally adapt the intervention (two separate intervention protocols will be adapted - one based on FG data and another based on DT data as described below), and obtain stakeholder input on acceptability and feasibility for the Hispanic/Latino autistic population. This provides a second way to measure the effectiveness of each stakeholder engagement method as we will have data to indicate which method (DT or FG) resulted in the highest-rated protocol. The data provided by this study will be used as a basis for a later comparative effectiveness study that will study the culturally adapted protocol's outcomes.
All sessions will be held in Spanish and/or English based on the groups' preferences. Since our intent is to hear the voices of Hispanic/Latino stakeholders, it seems valuable to hold focus groups in Spanish when the participants are Spanish as first language speakers (hereafter referred to as Spanish-first) with audio recordings and later transcription into English for analysis. To accommodate those who prefer English, we will make every effort to group these participants together. When, and if, the Spanish-first groups include participants who prefer English, we will have a Spanish to English translator available. In other words, we will be respectful of each participant's language to optimize their comfort in the engagement sessions.
This project addresses an urgent need to engage stakeholders as part of the research process from conceptualization to dissemination and the need for culturally sensitive evidence-based interventions for Hispanic/Latino autistic children. This project is being developed by a skilled and experienced team of investigators.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107-5084
- Thomas Jefferson University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Autistic person:
- confirmed diagnosis of autism spectrum disorder
- Hispanic/Latino
- received therapeutic services as a child; and
- willing and able (with i.e., language and cognitive skills) to participate in the design thinking or focus group session designed to learn about the facilitator and barriers to receipt of therapeutic services.
-
Parent/caregiver:
- Hispanic/Latino caregiver of an autistic child who receives or received therapeutic services such as occupational, physical, speech and language therapy
- willing to participate in the design thinking or focus group session designed to learn about the facilitator and barriers to receipt of therapeutic services.
-
Exclusion Criteria:
- Do not meet age for autistic individual or diagnostic criteria
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Design Thinking Group
A group of randomized participants (autistic adults, parents/caregivers, OT practitioners, teachers, and cultural experts) will participate in the Design Thinking (DT) process. |
Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test. |
|
Otro: Focus Group
A group of randomized participants (autistic adults, parents/caregivers, OT practitioners, teachers, and cultural experts) will participate in the Focus Group (FG) process. |
Participants attend the FG that includes the introduction. discussion, and reflection. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Stakeholder-Centric Engagement Evaluation (S-CEE) (Martinez et al., 2021)
Periodo de tiempo: Immediately following the one time engagement session
|
The Stakeholder-Centric Engagement Evaluation (S-CEE) is a measure used to assess the frequency and perceived quality of stakeholder engagement across 10 engagement domains, including: collaboration, communication, inclusion, transparency, learning, organizational structure, dissemination, and responsiveness to input. The measure evaluates two dimensions of engagement: frequency ("How Often") and quality ("How Well"). Each item is rated using a 5-point Likert scale. For "How Often," response options range from 1 ("Never") to 5 ("Always"). For "How Well," response options range from 1 ("Poor") to 5 ("Excellent"). Higher scores indicate greater frequency and higher perceived quality of stakeholder engagement. The S-CEE was administered to all participants immediately following the one-time engagement session to capture their perceptions of engagement. |
Immediately following the one time engagement session
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and the Feasibility of Intervention Measure (FIM) (Weiner et al., 2017)
Periodo de tiempo: Immediately following the cultural adaptation reviews.
|
The Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) are validated implementation outcome measures used to assess acceptability, appropriateness, and feasibility of the culturally adapted intervention based on the discussions in the focus groups and design thinking engagement sessions to improve access, use of therapy services, and strategies to adapt an evidence-based therapy intervention. AIM includes 5 items assessing the perceived acceptability of the intervention, IAM includes 4 items assessing the perceived appropriateness or fit of the intervention, and FIM includes 4 items assessing the perceived feasibility of implementing the intervention. Each item is rated using a 5-point Likert scale ranging from 1 ("Completely disagree") to 5 ("Completely agree"). Higher scores indicate greater perceived acceptability, appropriateness, and feasibility of the culturally adapted intervention. |
Immediately following the cultural adaptation reviews.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Roseann C Schaaf, Thomas Jefferson University
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Desordenes mentales
- Trastornos del neurodesarrollo
- Trastornos del desarrollo infantil generalizados
- Comportamiento
- Adherencia y Cumplimiento del Tratamiento
- Comportamiento de salud
- Aceptación del paciente de la atención médica
- Desorden del espectro autista
- Trastorno autista
- Participación del paciente
- Calidad, acceso y evaluación de la atención médica
- Técnicas de investigación
- Métodos epidemiológicos
- Recopilación de datos
- Mecanismos de evaluación de atención médica
- Calidad de la atención médica
- Salud pública
- Medio ambiente y salud pública
- Grupos focales
Otros números de identificación del estudio
- 2022C2-28939
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Publications in high-impact autism and occupational therapy journals and presentations at national and international autism research meetings.
Marco de tiempo para compartir IPD
Some de-identified data will be available following completion of the study and publication of findings.
Criterios de acceso compartido de IPD
Upon written request (reviewed by the principal investigator) information will be shared.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .